Abstract:Introduction Cancer immunotherapy and targeted therapy have yielded impressive clinical efficacy in acute B lymphoblastic leukemia (B-ALL). Despite the initial high complete remission (CR) rate following first-line therapy, treatment refractoriness and disease relapse remain are correlated with dismal survival. By the time the malignant cells generate, they are accompanied by a rich network of stromal cells and cytokines in bone marrow (BM). This tumor microenvironment (TME) represents an important feature of the biology of B-ALL but also shapes the clinical behavior of the disease. It remains to be confirmed whether the cellular composition and transcriptional heterogeneity impacts the clinical effects of B-ALL. Herein, we analyzed the immune cell infiltration features and related marker genes for B-ALL based on single cell RNA sequencing (scRNA-seq) data, which would be of significance for the development of novel immunotherapies. Methods ScRNA-seq data of 11373 BM cells from 3 B-ALL patients were obtained from the Gene Expression Omnibus (GEO, GSE153358). After quality control and data normalization, cell filtration and marker genes extraction were performed by the Seurat package. Principal component analysis (PCA) and t-distributed stochastic neighbor embedding (t-SNE) were then applied to cluster cells, following with cell types' definition and gene expression profiles in total subsets. Cell clustering was demonstrated using t-SNE-1 and t-SNE-2. In order to determine the cellular characteristics of TME cells mainly mediated by STING pathway, dendritic cell (DC) and B cell were extracted and further plotted gene expression including immunosuppressive molecules and STING pathway, respectively. The pseudo-time analysis was finally performed by Monocle package to display B cell development trajectory and gene expressions over time. Results 9 cell subsets in B-ALL BM, including naïve and memory CD4+ T cell, CD14+ monocyte, B cell, CD8+ T cell, FCGRA3+monocyte, nature killer (NK) cell, DC, and platelet, were identified based on t-SNE analysis (Fig.1A). Top 10 marker genes in each cell cluster were presented in heat map (Fig.1B). Through analyzing differentially expressed genes, we found that BM B cells hardly expressed PD-L1 (CD274), but partially carried TMEM173 (STING), NFKB1 (NF-κB) and GSDMD. In addition, immune cells in BM TME broadly distributed and highly expressed STING and NF-κB, indicating the potential response to type I innate immune response and higher sensitivity to STING agonists than PD-1 antibody (Fig.2A and B). Previous studies had revealed that STING pathway participated in the activation of DC following with production of type I IFNs. We further isolated DC from 9 subsets and profiled the gene expression features. T-SNE analysis revealed 3 subtypes of DC in BM, marker genes comparison further identified as monocyte derived DC, CD1C-CD14-DC and myeloid conventional DC. Cyclic GMP-AMP synthase (cGAS), STING and NF-κB were highly expressed in each type in compared with PDCD1 (PD-1) and highest existed on myeloid conventional DC (Fig.3). We then explored B cell subsets to determine whether STING pathway could induce cell pyroptosis in BM B cells. Different subgroup of B cells shared similar marker genes, companying with higher expression of NF-κB and GDSMD (Fig.4). Furthermore, pseudo-time analysis plotted the development trajectory of malignant B cells. The results showed that GSDMD gradually increased along with cell development, suggesting that STING agonist would be sensitive to mature B cells (Fig.5). Subsets analysis shown that anti-tumor immune response of DC and pyroptosis of B cell might be triggered through STING pathway activation. Conclusion Our study profiled for the first time the expression of STING pathway in BM DC and B cell from B-ALL patients based on single-cell transcriptome. Combination of STING agonist and conventional immunotherapy had been shown prospects in antitumor therapy. STING agonist is expected to be an adjuvant drug for B-ALL immunotherapies in the future. Keywords: Single-cell RNA sequencing; acute B lymphoblastic leukemia; STING; PD-1; immunotherapy. Disclosures No relevant conflicts of interest to declare.

Distinct Stromal Cell Populations Define the B-cell Acute Lymphoblastic Leukemia Microenvironment

Transcriptome-wide subtyping of pediatric and adult T cell acute lymphoblastic leukemia in an international study of 707 cases

The bone marrow microenvironment of pre-B acute lymphoblastic leukemia at single-cell resolution

No Hierarchical Heterogeneity in Adult B-ALL Lymphoid Neoplasia

Dynamic evolution of bone marrow adipocyte in B cell acute lymphoblastic leukemia: insights from diagnosis to post-chemotherapy

Bone Marrow Mesenchymal Stem Cells in Microenvironment Transform into Cancer-Associated Fibroblasts to Promote the Progression of B-cell Acute Lymphoblastic Leukemia

Single-cell RNA-seq analysis revealed the stemness of a specific cluster of B cells in acute lymphoblastic leukemia progression

Patient-Derived Bone Marrow Spheroids Reveal Leukemia-Initiating Cells Supported by Mesenchymal Hypoxic Niches in Pediatric B-ALL

Heterogeneity in chromatin structure drives core regulatory pathways in B-cell Acute Lymphoblastic Leukemia

A three-dimensional ex vivo model recapitulates in vivo features and unravels increased drug resistance in childhood acute lymphoblastic leukemia

Close interaction with bone marrow mesenchymal stromal cells induces the development of cancer stem cell-like immunophenotype in B cell precursor acute lymphoblastic leukemia cells

Single-cell transcriptomic analysis of the immune microenvironment in pediatric acute leukemia

Single-Cell Transcriptome Reveals the Role of Sting Pathway in Acute B Lymphoblastic Leukemia Bone Marrow Cells

Transcriptome Profiling Analyses Comprehensively Identified Molecular Subgroups Of B-Precursor Acute Lymphoblastic Leukemia

Abstract 271: The effects of B-cell acute lymphoblastic leukemia cells on the adipose tissue microenvironment

Abstract P07: Identification of the unique preleukemic bone marrow niche in acute myeloid leukemia

BM-MSCs Display Altered Gene Expression Profiles in B-cell Acute Lymphoblastic Leukemia Niches and Exert Pro-Proliferative Effects Via Overexpression of IFI6

Bone marrow mesenchymal stromal cells from acute myelogenous leukemia patients demonstrate adipogenic differentiation propensity with implications for leukemia cell support

Single-cell Profiling of T Cells Uncovers a Tissue-Resident Memory-Like T-cell Subset Associated with Bidirectional Prognosis for B-cell Acute Lymphoblastic Leukemia

The follicular lymphoma and chronic lymphocytic leukemia proliferative microenvironment at single-cell resolution

Single-cell RNA sequencing distinctly characterizes the wide heterogeneity in pediatric mixed phenotype acute leukemia